Xeris Biopharma Financial Ratios
NASDAQ: XERSHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
Xeris Biopharma ratio analysis
Xeris Biopharma earned a net margin of 0.2% in FY 2025, up from -27.0% a year earlier. Gross margin was 85.4% compared with a median of 79.5% over the prior 5 years. Return on equity reached 4.0%, meaning Xeris Biopharma generated 0.04 dollars of profit for every dollar of shareholders' equity.
Debt-to-equity stood at 16.10, and the current ratio was 2.19. Valuation ratios use the closing share price on each fiscal year-end date and diluted shares from the income statement; profitability and leverage ratios use reported annual figures. Current valuation multiples are on the statistics page.
Summary generated from market data by MetaCap's automated system. Methodology
Xeris Biopharma financial ratios (annual)
| Ratio | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Price / sales | 4.04 | 2.61 | 1.97 | 1.64 | 4.67 | 10.27 |
| Price / book | 86.14 | — | — | 3.99 | 2.43 | 6.21 |
| Gross margin | 85.4% | 81.9% | 82.5% | 79.5% | 73.1% | 54.4% |
| Operating margin | 8.5% | -16.6% | -26.8% | -74.3% | -232.2% | -408.8% |
| Net margin | 0.2% | -27.0% | -38.0% | -85.9% | -247.5% | -446.0% |
| Free cash flow margin | 9.8% | -18.2% | -28.7% | -93.3% | -194.8% | -396.1% |
| Return on equity (ROE) | 4.0% | — | — | -209.5% | -128.9% | -270.0% |
| Return on assets (ROA) | 0.1% | -17.0% | -19.3% | -27.5% | -40.3% | -57.3% |
| Debt / equity | 16.10 | — | — | 4.14 | 0.92 | 2.58 |
| Current ratio | 2.19 | 1.67 | 1.64 | 2.54 | 1.80 | 5.40 |
| Revenue growth | 43.7% | 23.9% | 48.7% | 122.3% | 142.7% | — |